Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease

Expert Opin Pharmacother. 2022 Feb;23(2):149-153. doi: 10.1080/14656566.2021.1980538. Epub 2021 Sep 20.

Authors

Lucia Brodosi^{1

2}, Francesca Marchignoli¹, Giulio Marchesini², Maria Letizia Petroni^{1

2}

Affiliations

¹ Department of Medical and Surgical Sciences, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
² University of Bologna, Bologna, Italy.

PMID: 34541981
DOI: 10.1080/14656566.2021.1980538

No abstract available

Publication types

Editorial

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease* / drug therapy
Risk Factors